Funded Project Details - FY2021
|Title:|| Functionally-selective parathyroid hormone analogs as therapeutics in metabolic bone disease|
Louis M. Luttrell
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2016 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Osteoporosis is an aging related condition characterized by progressive loss of bone mass and increasing bone fragility that affects many Veteran men and women. Given the tremendous morbidity and excess mortality associated with osteoporosis-related fracture, it is vital to the VA healthcare mission to explore novel strategies to reduce fracture risk. The only current FDA-approved anabolic therapy for severe osteoporosis is teriparatide [hPTH(1-34)], a conventional agonist of the type 1 parathyr...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.